Treatment-refractory ulcerative colitis responsive to indigo naturalis

Julie P Saiki, Johan OL Andreasson, Kevin V Grimes, Lyn R Frumkin, Elvi Sanjines, Matthew G Davidson, KT Park, Berkeley Limketkai

ABSTRACT

Background Indigo naturalis (IN) is an herbal medicine that has been used for ulcerative colitis with an unclear mechanism of action. Indigo and indirubin, its main constituents, are ligands of the aryl hydrocarbon receptor (AhR). We assessed the safety, efficacy, and colon AhR activity of IN given orally to patients with treatment-refractory ulcerative colitis. The role of AhR in IN benefit was further evaluated with an AhR antagonist in a murine colitis model.

Methods This open-label, dose-escalation study sequentially treated 11 patients with ulcerative colitis with either IN 500 mg/day or 1.5 g/day for 8 weeks, followed by a 4-week non-treatment period. The primary efficacy endpoint was clinical response at week 8, assessed by total Mayo score. Secondary endpoints included clinical remission, Ulcerative Colitis Endoscopic Index of Severity, quality of life, and colon AhR activity measured by cytochrome P450 1A1 (CYP1A1) RNA expression.

Results Ten of 11 (91%) patients, including 8/9 (89%) with moderate-to-severe disease, achieved a clinical response. Among these 10 patients, all had failed treatment with 5-aminosalicylic acid, 8 patients with a tumour necrosis factor (TNF)-alpha inhibitor, and 6 patients with TNF-alpha inhibitor and vedolizumab. Five patients were corticosteroid dependent. Clinical response was observed in all five patients who had been recommended for colectomy. Three patients achieved clinical remission. All patients experienced improved endoscopic severity and quality of life. Four weeks after treatment completion, six patients had worsened partial Mayo scores. Four patients progressed to colectomy after study completion. Colon CYP1A1 RNA expression increased 12 557-fold among patients treated for 8 weeks in this open-label dose-escalation pilot study of patients with UC refractory to prior treatment. Three patients achieved clinical remission. All patients experienced improved endoscopic severity and quality of life. Following treatment cessation, six patients worsened and four patients progressed to colectomy.

Conclusion IN attenuated disease in a murine colitis model, IN attenuated disease activity compared with vehicle control, and this benefit was abrogated when combined with an AhR antagonist.

Trial registration number NCT02442960.

INTRODUCTION

Ulcerative colitis (UC) is an idiopathic chronic inflammatory disease of the colon. Typical symptoms are abdominal pain, bloody diarrhoea, and cramping rectal pain. Symptoms of UC are often disruptive to the ability to work, and those with active disease have worsened quality of life. Four weeks after treatment completion, six patients progressed to colectomy after study completion. Colon CYP1A1 RNA expression increased 12 557-fold among patients treated for 8 weeks in this open-label dose-escalation pilot study of patients with UC refractory to prior treatment. Three patients achieved clinical remission. All patients experienced improved endoscopic severity and quality of life. Following treatment cessation, six patients worsened and four patients progressed to colectomy.

Conclusion IN attenuated disease in a murine colitis model, IN attenuated disease activity compared with vehicle control, and this benefit was abrogated when combined with an AhR antagonist.

Trial registration number NCT02442960.

INTRODUCTION

Ulcerative colitis (UC) is an idiopathic chronic inflammatory disease of the colon. Typical symptoms are abdominal pain, bloody diarrhoea, and cramping rectal pain. Symptoms of UC are often disruptive to the ability to work, and those with active disease.
experience a debilitating burden across most indices of quality of life. Uncontrolled disease can be associated with acute complications such as toxic megacolon and perforation, and chronic complications such as strictures, dysplasia, and colorectal cancer. The personal and economic burden of UC is reflected by high hospitalisation rates, emergency department visits, and decreased work productivity. Treatment of UC is suboptimal. More than half of patients with UC fail to respond to first-line 5-aminosalicylic acid (5-ASA) drugs and require escalation of therapy. Although biologics are currently the most effective therapeutics, few patients sustain long-term remission. Current UC treatments are also associated with risk of infection, malignancy, and pulmonary embolism. Ultimately, 14% of patients require a colectomy. There is a significant unmet need for more effective UC treatments.

Indigo naturalis (IN), also referred to as Qing-Dai, has a long history of use in traditional Chinese medicine. IN is an extract derived from stems and leaves of several plant species including Baphicacanthus cusia (Nees) Bremek of the Acanthacaea family, with indigo and indirubin considered its main organic ingredients. Benefits of IN for UC have been reported in several controlled, open-label, and retrospective studies, primarily in Japanese populations. A purported mechanism of action of IN in UC is activation of the aryl hydrocarbon receptor (AhR). Two main organic constituents, indigo and indirubin, are AhR agonists produced by gut microbiota. Activation of AhR is believed to lead to production of interleukin-22, which has been associated with enhanced epithelial barrier function, induction of metabolising enzymes, alteration of gut microbiota, downregulation of proinflammatory mediators, dampening of the immune response, and promotion of mucosal healing. Patients with inflammatory bowel disease have decreased AhR activity in gut microbiota. In a dextran sodium sulfate (DSS)-induced murine model of colitis, IN and indigo ameliorated colitis severity and this effect was absent in AhR-deficient mice.

A purposed mechanism of action of IN in UC is activation of the aryl hydrocarbon receptor (AhR). Two main organic constituents, indigo and indirubin, are AhR agonists produced by gut microbiota. Activation of AhR is believed to lead to production of interleukin-22, which has been associated with enhanced epithelial barrier function, induction of metabolising enzymes, alteration of gut microbiota, downregulation of proinflammatory mediators, dampening of the immune response, and promotion of mucosal healing. Patients with inflammatory bowel disease have decreased AhR activity in gut microbiota. In a dextran sodium sulfate (DSS)-induced murine model of colitis, IN and indigo ameliorated colitis severity and this effect was absent in AhR-deficient mice.

We conducted a phase Ib open-label study to evaluate the safety and efficacy of 8 weeks of treatment with oral IN followed by a 4-week non-treatment period in 11 patients with treatment-refractory UC, including patients recommended for colectomy who are typically excluded from UC clinical trials. AhR activity was measured by cytochrome P450 1A1 (CYP1A1) activation in colonic biopsy specimens collected after 8 weeks of IN treatment in selected patients. We also evaluated the effect of IN and concomitant administration of an AhR antagonist on disease activity in a murine colitis model.

METHODS AND ANALYSIS
Study design and selection of patients
The study is registered at ClinicalTrials.gov. Written informed consent (and assent, when appropriate) was obtained from all patients. Eligible patients were aged ≥13 and ≤75 years who were refractory or intolerant to 5-ASA. All patients had a biopsy-confirmed diagnosis of mild, moderate, or severe UC at screening, defined as a Mayo score of 3–12. Patients ≤17 years old were required to have active disease and be refractory or intolerant to 5-ASA, corticosteroids, small-molecule immunomodulators, and biologics or corticosteroid-dependent. Paediatric patients were required to have a body weight ≥45 kg to receive IN 1.5 g/day.

Additional entry criteria included Physician’s Global Assessment Mayo subscore ≥1 and endoscopic evidence of active mucosal disease as assessed by flexible sigmoidoscopy with Mayo endoscopic subscore ≥1. Exclusion criteria included patients with Crohn’s disease or indeterminate colitis; a change in therapy within 2 weeks before the baseline visit; use of immunomodulators; use of tobacco; diagnosis of diabetes, heart failure, unstable angina, liver or kidney disease; liver function test values greater than 1.5 times upper limit of normal; presence of Clostridium difficile, Salmonella, Shigella, Yersinia, Campylobacter, or enteropathogenic Escherichia coli in stool; and positive test for hepatitis C or hepatitis B.

During the study, patients were allowed to remain on stable UC-specific background therapy to include 5-ASA, glucocorticoids, or biologics if no change in dosing occurred, except for tapering of glucocorticoids if clinically warranted. Patients with clinical worsening requiring new UC-specific therapies or changes in dosing of background therapy, except glucocorticoid tapering, were to be discontinued from the study.

An independent data monitoring committee comprised four members who reviewed study progress and patient safety.

Randomisation, treatment administration, and dose
Patients were sequentially enrolled into one of two cohorts to receive treatment for 8 weeks followed by a 4-week non-treatment period. Cohort 1 comprised the first four patients (adults), who received 250 mg oral IN two times per day, and Cohort 2 comprised seven patients (five adults and two adolescents) who subsequently received 750 mg IN two times per day.

Patients were administered a gelatin capsule formulation of IN. The plant extract (drug substance) was processed by Fujian Xianyou Qingfeng Herbs Cooperative (Fujian Province, China) under Chinese Pharmacopoeia standards and Good Manufacturing Practice. Magnesium stearate and microcrystalline cellulose were added as excipients. The drug substance was characterised before encapsulation by high-performance liquid chromatography-ultraviolet (HPLC-UV), quantitative nuclear magnetic resonance, and inductively coupled plasma mass spectrometry to ensure purity. The drug product was tested for stability, microbial counts, and indigo (7.2%) and indirubin (0.44%) by HPLC-UV before release.
Patients were instructed to take IN capsules in the morning and evening after meals. The two IN doses (0.5 g and 1.5 g daily) were chosen because they were within a range used for varying conditions by thousands of patients in China, in UC clinical studies in Japan, within the lower range of recommended doses (1–3 g/d) in the Pharmacopoeia of the People’s Republic of China, and Chinese Materia Medica, and within the range (0.5–2 g/d) of the largest randomised, double-blind, placebo-controlled study that reported beneficial use of IN for 8 weeks in patients with UC.

**Efficacy assessments**

Disease activity in patients was evaluated based on total and partial Mayo scores obtained at baseline or screening and study weeks 2, 4, 6, 8, 10, and 12. The total Mayo scoring system for UC disease activity ranges from 0 to 12 points and is the sum of four subscores (stool frequency, rectal bleeding, endoscopic findings, and Physician’s Global Assessment), each graded from 0 to 3 with higher scores indicating more severe disease. A partial Mayo score is the total Mayo score without endoscopy. Flexible sigmoidoscopy for Mayo endoscopic subscore and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) scores was performed at screening and week 8. The UCEIS ranges from 0 to 8 points and consists of the following descriptors calculated as a simple sum: vascular pattern (scored 0–2); bleeding (scored 0–3); and erosions and ulcers (scored 0–3). Faecal calprotectin, a biomarker for intestinal inflammation, was evaluated at baseline and weeks 4, 8, and 12. Serum C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels were evaluated at baseline and week 8. The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) was evaluated at each visit to measure for disease-specific quality of life in patients with inflammatory bowel disease and ranges from 10 to 70, with higher scores indicating better quality of life. A daily patient diary was also collected to determine drug compliance and symptom severity, including number of bowel movements, presence of blood in stool, and general sense of well-being.

The primary efficacy endpoint was the proportion of patients with clinical response at week 8. Clinical response for patients with a total Mayo score at baseline ≥5 was defined as a decrease in the Mayo score from baseline of 30% or more and 3 or more points, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1. For patients with a total Mayo score at baseline of 3 or 4, clinical response was defined as a decrease from baseline in the Mayo score of at least 2 points and no individual subscore greater than 1. Secondary endpoints were proportion of patients with clinical remission at week 8 (Mayo score <3, with no individual subscore >1), change from baseline to week 8 in partial Mayo subscore (excluding endoscopic evaluation), change from baseline to week 8 for UCEIS score, change from baseline to week 8 in quality of life measured by SIBDQ, and change from baseline to week 8 in serum CRP, ESR, and faecal calprotectin levels.

CYP1A1 is expressed in the colon at low levels but is rapidly produced in response to AhR activation and is widely used to assess AhR activity. AhR activity was measured in colon biopsy samples in six patients at screening and week 8 and one patient who discontinued drug early where activity was measured at week 6. Messenger RNA was extracted from one to two biopsies per patient, and reverse transcriptase quantitative PCR was performed in quadruplicate to measure mean change from baseline in CYP1A1 expression normalised by 18S.

**Safety assessments**

Safety evaluations consisted of physical examination, vital signs, and laboratory evaluations at screening or baseline, day 1 (first drug administration), and weeks 2, 4, 8, and 12. Electrocardiograms were obtained at screening and week 2. Adverse events were collected throughout the 12-week study period.

**DSS-induced murine colitis model**

This experiment was conducted under the approval of the Institutional Animal Care and Use Committee of WuXi AppTec (Shanghai, China). All surgery was performed under sodium pentobarbital anaesthesia. Eight to 10-week-old C57BL/6 female mice were treated with oral 3% DSS (MP Biomedicals, Irvine, California, USA) in water for 7 days and subsequently changed to normal drinking water for 2 days. Mice (n=8/group) were concurrently treated two times per day for 9 days by oral gavage in four groups with IN (600 mg/kg/day) or vehicle, with or without concomitant AhR antagonist 3-methoxy-4-nitroflavone (MNF). MNF was delivered via intraperitoneal injection of 20 µM in 200 µl phosphate-buffered saline two times per day before oral gavage. Body weight and Disease Activity Index (DAI) scores (defined in Table 1) were evaluated daily by a blinded scorer. Mice were euthanised on day 9, 4–8 hours after the final dose.

**Table 1 Disease Activity Index (DAI) scoring system for dextran sodium sulfate-induced murine colitis model.** The DAI score (maximum 12) is the sum of the three subscores

<table>
<thead>
<tr>
<th>DAI score (maximum 12)</th>
<th>Subscore</th>
<th>Stool consistency</th>
<th>Bleeding</th>
<th>Weight loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Normal</td>
<td>Occult blood</td>
<td>&lt;1%</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Soft but still formed</td>
<td>Occult blood weak positive</td>
<td>1%–5%</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Very soft</td>
<td>Occult blood</td>
<td>5%–10%</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Diarrhoea</td>
<td>Bleeding</td>
<td>10%–20%</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Severe diarrhoea</td>
<td>Heavy bleeding</td>
<td>&gt;20%</td>
<td></td>
</tr>
</tbody>
</table>

**Statistical analysis**

Safety and efficacy were assessed on an intent-to-treat basis for all patients who received IN. Data were summarised using descriptive statistics for continuous variables and frequency and percentages for categorical variables. Adverse events were classified by system organ class and preferred term using Medical Dictionary for Regulatory Activities (MedDRA V.22). All p values were two-sided. Tests of significance were performed for categorical endpoints using Fisher’s exact test and continuous endpoints using a t-test.

**RESULTS**

Of 15 patients who signed informed consent, 4 failed in screening (laboratory values out of range, normal colonoscopy, two did not meet Mayo score criterion) and 11 were treated in this open-label, dose-escalation study conducted at Stanford University (Stanford Hospital and Clinics and Stanford Lucile Packard Children’s Hospital, Stanford, California, USA) between 15 June 2016 and 26 April 2017. Treatment was given for 8 weeks followed by a 4-week non-treatment period. During the study, study drug was noted to be out of specifications from high microbial load during routine quality control testing. As a result, the final two patients discontinued IN early, at week 2 (Patient 10) and week 6 (Patient 11). These patients received all week eight assessments at time of study drug discontinuation and completed the 4-week non-treatment follow-up period.

**Baseline and demographic characteristics**

Patient demographics, disease characteristics, and patient histories are listed in Table 2. Of 11 patients, 2 were adolescents (ages 14 and 15) and 9 were adults (ages 19–68 years). Most (9/11) patients had moderate or severe disease at baseline. All patients were refractory or intolerant to 5-ASA. Nine patients were refractory to tumour necrosis factor (TNF) inhibitors, six patients were refractory to both TNF inhibitors and vedolizumab used separately or in combination, and five patients were corticosteroid dependent. Five patients had been advised to undergo colectomy before seeking enrolment in the trial. At baseline, stool frequency, stool consistency, rectal bleeding, faecal calprotectin, and endoscopic findings were consistent with active UC.

**Efficacy**

Table 2 summarises key efficacy outcomes. Ten of 11 (91%) patients, including both patients who discontinued IN early (weeks 2 and 6), achieved a clinical response. Among these 10 patients, all had failed treatment to 5-ASA, 8 to TNF-alpha inhibitor, 6 to TNF-both alpha inhibitor and vedolizumab used separately or in combination, and 4 were corticosteroid dependent. Clinical response was also observed in all five patients who had a colectomy recommended before study entry.

Figure 1A,B show total and partial Mayo scores for each patient. The total Mayo score decreased in all patients

| Table 2: Patient demographics, baseline disease characteristics, and key efficacy outcomes. Mean (SD) are shown for both cohorts and summed total except calprotectin, which is shown as median values. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients Demographics Baseline disease characteristics Concomitant medications Disease history Key efficacy outcomes | Cohort 1 | 46 (16) | 6.5 (3.0) | 384 | 36 (16) | 0 | 50 | 0 | 50 | 75 | 50 | 50 | 50 | 100 | 50 |
| | Cohort 2 | 29 (17) | 8.9 (1.7) | 496 | 36 (10) | 29 | 86 | 29 | 57 | 86 | 57 | 43 | 43 | 86 | 14 |
| | Total | 35 (19) | 8.0 (2.6) | 478 | 36 (13) | 18 | 73 | 18 | 55 | 82 | 55 | 45 | 45 | 91 | 27 |
| | *Disease severity (Mayo score): mild (3–5), moderate (6–10), severe (11–12); WH, white, Hispanic or Latino; WN, white, not Hispanic or Latino. 5-ASA, 5-aminosalicylic acid; TNF, tumour necrosis factor. |

---

Clinical remission was achieved in three patients. All patients experienced improvement on endoscopy after 8 weeks of treatment, with a change from baseline in mean Mayo endoscopic subscore of 2.3 to 1.3 (p<0.0001) (figure 1C) and mean UCEIS score of 8.8 to 5.5 (p<0.0001) (figure 1D). Figure 2 shows representative colon endoscopy images before and after IN treatment for four patients. Of eight patients with a Mayo rectal bleeding subscore ≥1 at baseline, seven had a subscore of 0 at week 8 (figure 1E). All patients experienced improved quality of life as measured by the SIBDQ with a change from baseline in mean (SD) SIBDQ scores from 36.0 to 54.0 (p=0.001) (figure 1F). All eight patients receiving varying doses of concomitant glucocorticoids at baseline, including five who were steroid dependent, tapered their doses by week 8 with two patients not requiring any glucocorticoids at completion of IN treatment.

Four weeks after treatment completion, 6/11 (54%) patients had worsened partial Mayo scores and 8/11 (73%) patients had worsened SIBDQ scores compared with week 8. We are aware of at least four patients who have progressed to colectomy since study discontinuation.

### Safety

Table 3 summarises all adverse events. All four patients receiving IN 0.5 g/day and 5/7 (71.4%) patients receiving IN 1.5 g/day reported at least one adverse event. The most commonly reported adverse event was abdominal pain, reported by 3/4 (75%) patients receiving IN 0.5 g/day and 1/7 (14.3%) patients receiving IN 1.5 g/day. These events of abdominal pain were mild in intensity, transient, and judged to be unrelated to study drug by the investigator.

<table>
<thead>
<tr>
<th>MedDRA preferred term</th>
<th>(n=11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients reporting ≥1 adverse event</td>
<td>9 (82%)</td>
</tr>
<tr>
<td>Patients reporting ≥1 serious adverse event</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>4 (36%)</td>
</tr>
<tr>
<td>Headache</td>
<td>3 (27%)</td>
</tr>
<tr>
<td>Flatulence</td>
<td>2 (18%)</td>
</tr>
<tr>
<td>Orthostatic hypotension</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>Anorexia</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>Sepsis</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>Pharyngitis streptococcal</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>Faeces discoloured</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>Hypotension</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>Faeces hard</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>Ear pain</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>Chills</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>Acne</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>Pruritus</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>Eye haemorrhage</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>Rash</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>Frequent bowel movements</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>Polyuria</td>
<td>1 (9%)</td>
</tr>
</tbody>
</table>

**Table 3** Incidence of adverse events
One patient had two serious adverse events during the treatment period, orthostatic hypotension and sepsis, which resolved. These two events were unrelated to IN in the judgement of the investigator. No patient discontinued IN due to an adverse event. There were no clinically significant observations or trends of IN on laboratory assessments, ECG, vital signs, or physical examination findings during the study.

Biomarkers

Faecal calprotectin levels were measured for all visits for six patients (figure 3). Data are missing for five patients due to an inability to collect fresh stool samples and premature completion of the study for two patients. For the six patients with complete data, median calprotectin at baseline was 495.5 µg/g with one patient exceeding the upper reported quantifiable limit (>1000 µg/g). The median calprotectin value at week 8 was reduced to 73.5 µg/g with one patient below the lower limit of quantitation (<15.6 µg/g). All six patients had a clinically meaningful reduction in calprotectin levels (range of reduction, 294–907 µg/g) from baseline to week 8. Neither CRP nor ESR showed marked elevations at baseline.

AhR activation in human colon biopsies after IN treatment

Figure 4 shows an increase (12 557-fold) in mean expression of CYP1A1 between baseline and week 8 in colon tissue from seven patients, measured by quantitative real-time PCR. The black line indicates average normalised baseline expression and the red line marks the average normalised increase (12 557-fold). Error bars represent propagated errors from CYP1A1 (n=4) and 18S (n=4) levels measured simultaneously for sample normalisation. CYP1A1, cytochrome P450 1A1.

DISCUSSION

This open-label pilot study evaluated the safety and efficacy of 8 weeks of oral IN use in 11 patients with treatment-refractory UC. All patients showed marked endoscopic and clinical improvement from baseline to week 8 that is not expected with the natural history of treatment-refractory UC.1 Of note, a clinical response was observed at 2 weeks and 6 weeks in two patients who discontinued treatment early due to study drug being out of specification, suggesting that benefit may occur shortly after initiation of IN.12 Following discontinuation of treatment, six patients had worsening of partial Mayo scores, eight patients had worsened SIBDQ scores, and four patients progressed to colectomy.

Placebo effects are prominent in controlled trials of UC therapies.37 These effects are lower in patients with more severe baseline disease activity and prior exposure to TNF antagonists and vedolizumab.37 Our study population was refractory or intolerant to multiple agents at study entry and five patients had been recommended for colectomy, which is typically an exclusion criterion that precludes patients from entering UC clinical drug

Figure 3 Calprotectin levels at weeks 0, 4, 8, and 12 for six patients. Normal levels are ≤50 µg/g, 200 µg/g is commonly considered positive for inflammatory bowel disease, and the upper quantifiable limit was 1000 µg/g.

Figure 4 CYP1A1 expression in one to two colon tissues each from seven patients, measured by quantitative real-time PCR. The black line indicates average normalised baseline expression and the red line marks the average normalised increase (12 557-fold). Error bars represent propagated errors from CYP1A1 (n=4) and 18S (n=4) levels measured simultaneously for sample normalisation. CYP1A1, cytochrome P450 1A1.

AhR activation in human colon biopsies after IN treatment

AhR ligands indigo and indirubin being rapidly metabolised by CYP1A1.36 Small molecule AhR antagonist abrogates activity of IN in DSS murine colitis model

Mice with DSS-induced colitis treated with IN (600 mg/kg) had significant improvements in DAI (mean±SEM, 4.5±1.2 vs 11±0.49, p<0.001) and body weight (17.4±0.7 vs 14.8±0.5, p=0.01) at day 9 compared with vehicle control. Administration of MNF (8 nmol/day), an AhR antagonist, abrogated the benefit of IN. Mice treated with IN and MNF had significantly worse DAI scores (9.4±1.2, p<0.01) and body weights (15.7±0.3, p<0.01) at day 9 compared with mice treated with IN alone. Mice treated with IN and MNF did not significantly differ compared with mice treated with MNF alone in DAI (10.5±0.9, p=0.3) or body weight (14.9±0.6, p=0.19) at day 9 (figure 5).
AhR agonist that achieves the same therapeutic effect as IN could improve quality control. Moreover, delivery of a locally acting AhR agonist in a colon-targeted delayed-release dosage form could potentially improve the safety profile by minimising systemic exposure, aberrant AhR stimulation, and rare but serious events such as PAH.

In conclusion, we expand on the findings of Naganuma et al that IN resulted in benefit in Japanese patients with treatment-refractory UC. Our study demonstrated benefit of IN in a Western population with a more extensive history of intolerance or failure with prior UC treatments. In addition, the study also clarifies the role of AhR activation as the primary mechanism of this benefit, consistent with the attenuation of colitis through other AhR activators in multiple animal models. Limitations of this study are its open-label nature and small sample size. Further investigation with a well-controlled study and an adequate number of patients to evaluate the use of a colon-targeted AhR agonist in patients with treatment-refractory UC is warranted.

**Acknowledgements** The authors thank all study patients and their families. We acknowledge the members of the data monitoring committee and thank SPARK at Stanford advisors, including Daria Mochly-Rosen, Robert Lum, Steve Schow, and Carol Karp, for their scientific, regulatory, and manufacturing guidance. David Goodkin provided helpful advice and critical review.

**Contributors** BL was the sponsor-investigator of the clinical study conducted under an investigator-initiated Investigational New Drug application. JPS and JOLA designed the clinical study and preclinical experiments, monitored study data collection, and analysed the data. KV and LRF designed the clinical study and analysed the data. ES oversaw and conducted study procedures and specimen collection. MGD designed preclinical experiments and analysed data. BL and KTP were study investigators and contributed to data collection and interpretation. JPS and LRF wrote the first draft of the manuscript and all authors participated in the review. BL is guarantor of the work.

**Funding** The clinical study and experiments were supported by SPARK at Stanford, Weston Havens Foundation, and Azora Therapeutics.

**Competing interests** JPS and MGD are employed by and have equity in Azora Therapeutics and are co-inventors on a patent for compositions comprising indigo and/or an indigo derivative. JOLA has equity in Azora Therapeutics and is a co-inventor on a patent for compositions comprising indigo and/or an indigo derivative. LRF has stock in Azora Therapeutics related to advisory activities. BL is currently employed at the University of California, Los Angeles and has stock in Azora Therapeutics related to advisory activities. KTP declares no competing interest during the study, is an employee of Genentech, and shareholder of the Roche Group.

**Patient consent for publication** Not applicable.

**Ethics approval** The study was approved by the Stanford University Institutional Review Board and conducted in compliance with Good Clinical Practice guidelines, Declaration of Helsinki, and regulatory requirements.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. De-identified patient data that support the findings of this study are available from the corresponding author upon reasonable request.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**

Julie P Saiki http://orcid.org/0000-0003-0628-1686
Lyn R Frumin http://orcid.org/0000-0002-5227-3284
REFERENCES

receptor (AhR) ligands, inhibit gut inflammatory signals. *Front Pharmacol* 2019;10:380.


